Methods of using microneedle vaccine formulations to elicit in animals protective immunity against rabies virus
AssigneesMerial Limited, Georgia Tech Research Corporation
InventorsYu-Wei Chiang, Mark R. Prausnitz, Kristopher Daniel DeWitt, Jaya Arya
Life of this patent
Estimating the term…
Abstract
The present invention relates to microneedle vaccine formulations, as well as methods of use thereof to provide animals, including canines, protective immunity against infection and disease caused by rabies viruses. Once placed onto the skin of the animals, the microneedle formulations dissolve quickly into the surrounding skin, where the antigens then elicit in the animals high and protective levels of rabies virus neutralizing antibodies.
Claims28
A safe and effective microneedle Rabies virus vaccine composition, which when administered to the pinna of an animal's ear elicits in said animal a safe and protective immune response against subsequent virulent Rabies virus challenge, comprising an immunogen comprising:
- (a) an effective amount of a plasmid DNA vector expressing in vivo in said animal a protective Rabies G antigen,
- (b) an effective amount of an attenuated recombinant viral vector expressing in vivo in said animal a protective Rabies G antigen, or
- (c) an effective amount of a protective Rabies G polypeptide;
- and
- a sugar and a bioerodible polymer;
- and
- wherein the composition is formulated as bio-absorbable microneedles;
- and
- wherein the composition is stable for at least 3 weeks at 4° C.
Dependencies are inferred from the claim text.